Is There A Clinical Benefit Derived From Using Low Dose Prednisone With First Line Docetaxel Treatment In Men With Castrate Resistant Prostate Cancer?
There have been some randomized studies that have shown that when prednisone is used in combination with docetaxel (chemotherapy) there is an improved survival in men who have metastatic castration-resistant prostate cancer (mCRPC). To add to our understanding of the possible clinical value of this combination of drugs some researchers have retrospectively evaluated whether the co-administration of low-dose glucocorticoids with docetaxel has clinical benefits. They evaluated the records of 358 men with metastatic castration-resistant prostate cancer (mCRPC) who were treated with either docetaxel or docetaxel and prednisone. They found that the men treated with docetaxel alone had a higher incidence [...]